了解肿瘤-宿主免疫相互作用和肺癌对免疫治疗的反应机制至关重要。目前用于研究这一问题的临床前模型通常无法捕捉人类肺癌的复杂性，并导致不确定的结果。为了弥补这一差距，我们引入了两种新的鼠单克隆肺癌细胞系，用于免疫活性原位模型。我们展示了我们的细胞系如何表现出在人类肺腺癌患者中观察到的免疫组织化学蛋白表达（TTF-1、NapA、PD-L1）和常见驱动突变（KRAS、p53 和 p110α），以及我们的原位模型如何对联合免疫疗法做出反应体内的方式密切反映当前的临床结果。这些新的肺腺癌细胞系为研究肿瘤和免疫系统之间复杂的动态提供了一个宝贵的临床相关平台，因此可能有助于更深入地了解肺癌治疗的免疫治疗方法。

Understanding tumor-host immune interactions and the mechanisms of lung cancer response to immunotherapy is crucial. Current preclinical models used to study this often fall short of capturing the complexities of human lung cancer and lead to inconclusive results. To bridge the gap, we introduce two new murine monoclonal lung cancer cell lines for use in immunocompetent orthotopic models. We demonstrate how our cell lines exhibit immunohistochemical protein expression (TTF-1, NapA, PD-L1) and common driver mutations (KRAS, p53, and p110α) seen in human lung adenocarcinoma patients, and how our orthotopic models respond to combination immunotherapy in vivo in a way that closely mirrors current clinical outcomes. These new lung adenocarcinoma cell lines provide an invaluable, clinically relevant platform for investigating the intricate dynamics between tumor and the immune system, and thus potentially contributes to a deeper understanding of immunotherapeutic approaches to lung cancer treatment.